McKesson Corporation is a leading healthcare services and information technology company that operates in the United States and internationally.
Their stock is listed on the New York Stock Exchange (NYSE) under the ticker symbol MCK.
McKesson's revenue for 2022 was $263.7 billion, a significant increase from $232.8 billion in 2020.
The company's focus on healthcare services and technology has helped it expand its reach and capabilities in the industry.
Financial Data
McKesson's revenue has seen a significant increase, reaching $308.95 billion in 2023, a 11.65% rise from the previous year.
In 2025, the company is estimated to reach a revenue of $360,015, with an average estimate of $395,510 by 2026.
McKesson's earnings per share (EPS) are expected to grow, with an estimated EPS of $32.68 in 2025 and $36.78 in 2026.
Here's a breakdown of McKesson's estimated financial performance for the next few years:
McKesson's financial performance is expected to continue growing, with an estimated revenue increase of 5.81% from the previous year.
Financial Performance
McKesson's revenue is estimated to reach $360,015 in 2025, $395,510 in 2026, and $517,857 in 2029.
The company's dividend has been decreasing, with a projected yield of 0.42% in 2025 and 0.39% in 2026.
McKesson's earnings per share (EPS) is expected to increase, reaching $53.78 in 2029.
Here's a breakdown of McKesson's estimated earnings per share (EPS) for the next few years:
McKesson's price-to-earnings (P/E) ratio is projected to decrease, reaching 11.25 in 2029.
The company's net profit is expected to increase, reaching $5,929 in 2029.
McKesson's cash flow from operations is projected to increase, reaching $7,885 in 2029.
The company's free cash flow is expected to increase, reaching $7,049 in 2029.
McKesson's book value per share is projected to increase, reaching $11.32 in 2026.
The company's net debt is expected to decrease, reaching -$2,894 in 2026.
McKesson's capital expenditure is projected to increase, reaching $836 in 2029.
The company's research and development expenses are not available for the next few years.
McKesson's selling, general, and administrative expenses are projected to increase, reaching $10,280 in 2027.
The company's shareholder's equity is expected to increase, reaching $1,660 in 2029.
McKesson's total assets are projected to increase, reaching $102,502 in 2029.
The average earnings estimate for McKesson's next quarter is $8.231 USD, with a high estimate of $8.43 and a low estimate of $7.95.
The growth rate estimate for McKesson's earnings is +5.81% year over year.
McKesson's next earnings report is expected to be released on July 30, 2025, with an estimated earnings per share of $8.231 USD.
Dividend Calendar
McKesson Corp. has a long history of paying dividends to its shareholders. The company's dividend has been steadily increasing over the years, with the highest dividend paid in 2000 being $1.14 per share.
The dividend yield, which is the ratio of the annual dividend payment to the stock's current price, has also been steadily increasing. In 2015, the dividend yield was 0.42%, while in 2024, it was 0.45%.
Here is a breakdown of McKesson's dividend history:
As you can see, McKesson's dividend has been steadily increasing over the years, providing a relatively stable source of income for shareholders.
Company Information
McKesson is a leading healthcare services and information technology company. Founded in 1833, it has a rich history of providing innovative solutions to the healthcare industry.
Headquartered in Irving, Texas, McKesson operates globally with a diverse workforce of over 50,000 employees.
The company's revenue for 2020 was approximately $231 billion.
Market Analysis
Analysts are optimistic about McKesson's future performance, with an average rating of "Strong Buy" from 13 analysts, forecasting a 12-month stock price of $637.77, a 5.78% increase from the latest price.
McKesson has reported better-than-expected second-quarter financial results, which has led to analysts boosting their forecasts.
The company has raised its annual profit forecast, driven by increased sales in its U.S. pharmaceuticals segment on robust demand for specialty and branded drugs.
The Barchart Technical Opinion rating is a 72% Buy, indicating a strong short-term outlook, but warns that the market is approaching overbought territory, so be watchful of a trend reversal.
Oversold stocks at support often experience a rally, so it's worth keeping an eye on McKesson's price levels and momentum.
News and Events
McKesson has a history of releasing strong earnings reports, with the highest actual EPS being $25.030 USD for the Annual General Meeting in 2023. This is a significant increase from their lowest actual EPS of $-0.040 USD for the Q3 2022 Earnings Release.
Their most recent earnings reports have shown a steady growth trend, with the Q1 2024 Earnings Release reporting $7.020 USD in actual EPS and the Q3 2023 Earnings Release reporting $7.660 USD in actual EPS. This growth is a promising sign for investors.
Here are some key upcoming events for McKesson:
Calendar
McKesson has a few notable events on its calendar. One of them is the Q3 2025 Earnings Release, which is estimated to be around 8.123 USD.
The Q4 2025 Earnings Release is set to happen on May 13th, 2025, and is estimated to be around 9.645 USD. This is a significant event in the company's financial calendar.
McKesson's Q1 2026 Earnings Release is estimated to be around 8.231 USD and is scheduled for July 30th, 2025. This is a key date to keep in mind for investors.
Here are the upcoming earnings release dates and estimates:
The Q2 2026 Earnings Release is set to happen on November 4th, 2025, and is estimated to be around 8.626 USD.
Past Events
McKesson has held several Annual General Meetings, with the most recent one taking place on 07/31/2024, where the actual EPS was 22.390 USD.
The company has also released its earnings reports for Q4 2024, which was announced on 05/07/2024, with an EPS of 6.020 USD.
McKesson's Q3 2024 earnings release showed an EPS of 4.420 USD, which was announced on 02/07/2024.
Here's a list of McKesson's past earnings reports:
McKesson's past earnings reports show a range of EPS values, from 2.470 USD to 7.660 USD.
News Corp Execs Selling Stocks
Executives at News Corp are selling stocks, joining other notable insider trades.
The Nasdaq 100 closed lower by over 500 points during Friday's session.
Frequently Asked Questions
Is McKesson a good stock to buy now?
McKesson Corp. has a strong buy rating from 13 analysts, with an average price target of $653.00, suggesting it may be a good investment opportunity, but it's essential to do your own research before making a decision.
What is the future outlook for McKesson?
According to analyst forecasts, McKesson stock is expected to increase by 11.18% to around $639, with a potential range of $505 to $713. This suggests a positive future outlook for the company.
Why is McKesson dropping?
McKesson's stock is dropping due to lower-than-expected revenue in its fiscal first quarter. The company's results fell short of analysts' predictions, causing investor concern.
What is the stock price forecast for McKesson in 2025?
Analysts forecast McKesson's stock price to range between $622.00 and $715.00 USD in 2025, with a predicted average of $671.79 USD. This estimate is based on current market analysis and may be subject to change.
What is the symbol for McKesson?
The symbol for McKesson Corporation is MCK. It is listed on the New York Stock Exchange.
Featured Images: pexels.com
